POLYPHARMACY AND INTERACTIONS - WHAT IS A PHARMACIST ROLE?

Author(s)

Snopkova M1, Szmicsekova K1, Sukel O2
1Comenius University, Faculty of Pharmacy, Bratislava, Slovakia, 2Slovak Chamber of Pharmacists, Bratislava, Slovakia

OBJECTIVES: Pharmacists have the potential to improve health system interventions, medicine therapy management and polypharmacy. There are many negative consequences associated with polypharmacy. The burden of taking multiple medications can be associated with greater health care costs and an increased clinical risk (adverse drug events, drug-interactions, drug duplicity and possibly medication non-adherence). In the healthcare system of Slovakia there is not yet defined the position of a clinical pharmacist (in a community pharmacy) as a control and counseling subject.

METHODS: Data are from patient visits to pharmacy and outpatient. We examined patients and practitioners requirements between january and march 2017 and expose a "medicines report" requiring medical interventions. The medicines report contains: type, number and clinical evidence of interaction, recommendation regarding the presence of the interaction, recommendation for future (theoretical) therapy, consideration of patient's co-payment and drug duplication.

RESULTS: Reviewing and monitoring the use of drugs by 29 patients it was identified a presence of interactions. The analysed patients were taking from 5 to 20 medicines (average 9.17; SD=4.61; median=7 drugs/patient). There were identified together 218 interactions C (monitor therapy), D (consider therapy modification) or X (avoid combination) type (average=7.52; SD=9.35; median=7). The most clinical relevant interactions were present in group C (85.32%; average=6.41; SD=7.89; median=4). In the next group D were 14.22% interactions (average=1.07; SD=2.23; median=0) and in the group X was 1 interaction (0.46%; average=0.03; SD=0.19; median=0).

CONCLUSIONS: The medicine report provides amendments which aimed to improve the treatment of patients and contribute to their quality of life including decreasing patient's co-payment. Need to be developed the medicines report methodology and quantify the clinical and economic value of this intervention. The condition is cooperation between stakeholders, healthcare providers and patients.

Conference/Value in Health Info

2017-11, ISPOR Europe 2017, Glasgow, Scotland

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PHS98

Topic

Health Service Delivery & Process of Care, Organizational Practices

Topic Subcategory

Academic & Educational, Hospital and Clinical Practices, Prescribing Behavior

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×